Sanofi EBITDA 2006-2018 | SNY

Sanofi annual and quarterly EBITDA history from 2006 to 2018. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Sanofi EBITDA for the quarter ending March 31, 2018 was $1.549B, a 16.33% decline year-over-year.
  • Sanofi EBITDA for the twelve months ending March 31, 2018 was $6.768B, a 16.84% decline year-over-year.
  • Sanofi 2017 annual EBITDA was $11.236B, a 0.08% decline from 2016.
  • Sanofi 2016 annual EBITDA was $11.245B, a 4.59% decline from 2015.
  • Sanofi 2015 annual EBITDA was $11.786B, a 13.05% decline from 2014.
Sanofi Annual EBITDA
(Millions of US $)
2017 $11,236
2016 $11,245
2015 $11,786
2014 $13,555
2013 $15,605
2012 $14,858
2011 $18,179
2010 $17,307
2009 $17,891
2008 $18,306
2007 $14,762
2006 $14,875
2005 $13,429
Sanofi Quarterly EBITDA
(Millions of US $)
Q1 2018 $1,549
Q4 2017 $1,188
Q3 2017 $2,434
Q2 2017 $1,596
Q1 2017 $1,851
Q4 2016 $1,842
Q3 2016 $2,722
Q2 2016 $1,724
Q1 2016 $1,305
Q3 2015 $2,308
Q2 2015 $2,131
Q2 2014 $1,977
Q2 2013 $1,545
Q2 2012 $5,370
Q1 2012 $2,582
Q4 2011 $2,047
Q3 2011 $2,184
Q2 2011 $1,596
Q1 2011 $3,061
Q4 2010 $1,360
Q3 2010 $2,954
Q2 2010 $2,940
Q1 2010 $1,961
Q4 2009 $1,057
Q3 2009 $2,874
Q2 2009 $2,908
Q1 2009 $1,973
Q4 2008 $1,645
Q3 2008 $2,094
Q2 2008 $1,997
Q1 2008 $2,254
Q4 2007 $1,515
Q3 2007 $2,452
Q2 2007 $1,561
Q1 2007 $2,399
Q4 2006 $1,400
Q3 2006 $1,638
Q2 2006 $1,417
Q1 2006 $1,394
Q4 2005 $-509
Q3 2005 $2,857
Q2 2005 $1,078
Q1 2005 $1,057
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $113.065B $39.599B
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $387.009B 18.15
Pfizer (PFE) United States $255.437B 14.40
Novartis AG (NVS) Switzerland $202.383B 17.29
Merck (MRK) United States $199.761B 17.31
AbbVie (ABBV) United States $132.837B 11.79
Eli Lilly (LLY) United States $116.324B 20.45
Novo Nordisk (NVO) Denmark $108.639B 17.64
AstraZeneca (AZN) United Kingdom $104.862B 13.02
GlaxoSmithKline (GSK) United Kingdom $101.405B 13.63
Bristol-Myers Squibb (BMY) United States $85.837B 14.14